Latest Research Study on Neuroendocrine Cancer
Neuroendocrine Cancer Market size was valued at USD million in 2021 and is estimated to reach USD million by 2031, growing at a CAGR of 10.6% during the forecast period (2024-2031).
Neuroendocrine Cancer is a rare type of cancer that develops in the neuroendocrine cells, which are specialized cells found throughout the body that produce hormones and regulate various bodily functions. These tumors can form in different organs, including the lungs, pancreas, intestines, and adrenal glands. While some neuroendocrine tumors (NETs) grow slowly and remain localized, others can be more aggressive and spread to other parts of the body.
Neuroendocrine cancer is classified based on its location, hormone production, and growth rate. Functional NETs produce excess hormones, leading to noticeable symptoms such as flushing, diarrhea, and high blood pressure, while non-functional NETs may remain undetected until they grow larger. Common types include pancreatic NETs (pNETs), lung NETs, and gastrointestinal NETs (GI-NETs).
The exact cause of neuroendocrine cancer is unclear, but genetic mutations, hereditary conditions, and prolonged inflammation may contribute to its development. Early diagnosis is often challenging due to vague symptoms, but advanced imaging techniques, biomarker testing, and biopsies help in detection. Treatment options depend on the tumor’s type and stage and may include surgery, targeted therapy, hormone therapy, chemotherapy, and radiotherapy.
Download Free Sample PDF: https://www.datamintelligence.com/download-sample/neuroendocrine-cancer-market
Market Growth Drivers:
The increasing research and development and the growing prevalence of neuroendocrine cancer are expected to drive market growth.
Immunotherapy, also known as biologic therapy, is a treatment approach designed to enhance the body’s natural defenses to fight cancer. Researchers are exploring cancer vaccines for neuroendocrine tumors (NETs), along with new therapies that target the PD-1 protein. PD-1, found on T cells (a type of white blood cell), acts as a brake on the immune system, preventing it from attacking tumors. By blocking PD-1, the immune system becomes more effective at recognizing and eliminating cancer cells.
One breakthrough in immunotherapy is Atezolizumab (Tecentriq), a PD-L1 inhibitor approved by the FDA for treating metastatic small cell lung cancer in combination with carboplatin and etoposide chemotherapy. While lung NETs are distinct from other lung cancers, the success of atezolizumab suggests the potential for further research into immunotherapy for lung NETs.
Additionally, researchers are investigating chimeric antigen receptor (CAR) T-cell therapy, which involves extracting a patient’s T cells, modifying them to target cancer cells, and reinfusing them into the body. When combined with antibody-drug conjugates, a form of targeted therapy, this approach shows promise in advancing NET treatment. As research continues, immunotherapy is emerging as a crucial area in the fight against neuroendocrine tumors.
Market Segments:
- By Drug Type: Sunitinib Malate, Everolimus, Lanreotide, Octreotide, Others
- By Treatment: Surgery, Chemotherapy, Targeted Therapy, Radiotherapy, Others
- By End user: Hospitals, Oncology Centers, Ambulatory Surgical Center, Others
- By Region: North America, Latin America, Europe, Asia Pacific, Middle East and Africa
Top Companies:
- Novartis AG
- Pfizer Inc.
- Ipsen
- Tarveda Therapeutics
- Progenics Pharmaceuticals, Inc.
- Hutchison Medipharma Limited
- Dauntless Pharmaceuticals Inc.
- Exelixis, Inc.
- Advanced Accelerator Applications
- Argos Therapeutics Inc
Customize Your Scope: https://www.datamintelligence.com/customize/neuroendocrine-cancer-market
Regional Growth
North America region holds the largest market share in the global Neuroendocrine Cancer market
The rising prevalence of neuroendocrine cancer and increasing R&D investments are key drivers of market growth. In the United States, approximately 12,000 new cases of neuroendocrine tumors (NETs) are diagnosed annually, with an estimated 175,000 people currently living with the condition. The incidence of NETs has been steadily increasing over the years.
Cancer research has been a major focus of R&D funding, supported not only by research foundations but also by government initiatives worldwide. For instance, in January 2021, the Neuroendocrine Tumor Research Foundation (NETRF) awarded $2.62 million in grants for advanced research aimed at developing innovative therapeutics for NETs. Over the past 15 years, NETRF has invested $30 million in research, demonstrating a strong commitment to advancing treatment options.
With ongoing research efforts and significant funding, North America is expected to hold the largest market share in the forecast period, driven by its robust healthcare infrastructure and continued scientific advancements.
